Nambi V - Search Results

1

Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting.

Bandeali SJ, Kayani WT, Lee VV, Pan W, Elayda MA, Nambi V, Jneid HM, Alam M, Wilson JM, Birnbaum Y, Ballantyne CM, Virani SS. Bandeali SJ, et al. Among authors: nambi v. Am J Cardiol. 2012 Oct 1;110(7):919-23. doi: 10.1016/j.amjcard.2012.05.021. Epub 2012 Jun 20. Am J Cardiol. 2012. PMID: 22727178

2

QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias.

Kalahasti V, Nambi V, Martin DO, Lam CT, Yamada D, Wilkoff BL, Niebauer MJ, Jaeger FJ, Tchou PJ, Chung MK. Kalahasti V, et al. Among authors: nambi v. Am J Cardiol. 2003 Oct 1;92(7):798-803. doi: 10.1016/s0002-9149(03)00886-5. Am J Cardiol. 2003. PMID: 14516879

3

ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2004 Sep;6(5):353-8. doi: 10.1007/s11883-004-0046-1. Curr Atheroscler Rep. 2004. PMID: 15296701 Review.

4

Apolipoprotein A-I and high-density lipoprotein: is this the beginning of the era of noninvasive angioplasty?

Ballantyne CM, Nambi V. Ballantyne CM, et al. Among authors: nambi v. J Am Coll Cardiol. 2004 Oct 6;44(7):1436-8. doi: 10.1016/j.jacc.2004.07.018. J Am Coll Cardiol. 2004. PMID: 15464324 Free article. Review. No abstract available.

5

Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2005 Feb;7(1):22-8. doi: 10.1007/s11883-005-0071-8. Curr Atheroscler Rep. 2005. PMID: 15683598 Review.

6

Markers of inflammation and their clinical significance.

Ballantyne CM, Nambi V. Ballantyne CM, et al. Among authors: nambi v. Atheroscler Suppl. 2005 May;6(2):21-9. doi: 10.1016/j.atherosclerosissup.2005.02.005. Atheroscler Suppl. 2005. PMID: 15823493 Review.

7

Effectiveness of percutaneous intervention for patients with obstructive hypertrophic cardiomyopathy and coronary artery disease.

Nambi V, Buergler JM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Nambi V, et al. Am J Cardiol. 2005 Aug 15;96(4):580-1. doi: 10.1016/j.amjcard.2005.04.023. Am J Cardiol. 2005. PMID: 16098315

8

Fat, fit, and leading the charge: the evolution of measuring high-density lipoprotein subpopulations.

Nambi V, Ballantyne CM. Nambi V, et al. Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2013-5. doi: 10.1161/01.ATV.0000186043.86570.4f. Arterioscler Thromb Vasc Biol. 2005. PMID: 16199755 No abstract available.

9

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Nambi V, Ballantyne CM. Nambi V, et al. Curr Atheroscler Rep. 2006 Sep;8(5):374-81. doi: 10.1007/s11883-006-0034-8. Curr Atheroscler Rep. 2006. PMID: 16901407 Review.

10

Combination therapy with statins and omega-3 fatty acids.

Nambi V, Ballantyne CM. Nambi V, et al. Am J Cardiol. 2006 Aug 21;98(4A):34i-38i. doi: 10.1016/j.amjcard.2005.12.025. Epub 2006 May 30. Am J Cardiol. 2006. PMID: 16919515 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters